Olijnik, Aude-Anais http://orcid.org/0000-0002-0980-6663
Rodriguez-Romera, Antonio
Wong, Zoƫ C.
Shen, Yuqi
Reyat, Jasmeet S. http://orcid.org/0000-0003-3247-9186
Jooss, Natalie J. http://orcid.org/0000-0002-2314-4993
Rayes, Julie
Psaila, Bethan http://orcid.org/0000-0001-8198-9663
Khan, Abdullah O. http://orcid.org/0000-0003-0825-3179
Funding for this research was provided by:
Wellcome Trust (218649/A/19/Z)
Wellcome Trust (218649/Z/19/Z)
Cancer Research UK (C67633/A29034)
Article History
Received: 28 February 2023
Accepted: 22 December 2023
First Online: 26 March 2024
Competing interests
: B.P.: Alethiomics (co-founder, equity, consultancy, research funding), Constellation Therapeutics (consultancy), Blueprint Medicines (advisory board), Galecto (research funding), Novartis (paid speaking engagements), GSK (advisory board). A.O.K.: Alethiomics (consultancy). The other authors have no conflicts of interest to declare that are relevant to the content of this article. A patent has been filed by A.O.K. and B.P. relating to work described in this paper (GB2202025.9 and GB221664.47 (WO/2023/156774), PCT/GB2023/050348).